We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of AVEO Pharmaceuticals, Inc. (“AVEO” or the “Company”) (NASDAQ: AVEO), in connection with the proposed acquisition of the Company by LG Chem, Ltd.  Under the terms of the merger agreement, the Company’s shareholders will receive $15.00 in cash for each share of AVEO common stock owned. The transaction is valued at approximately $566 million.

Weiss Law is investigating whether (i) AVEO’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $15.00 per-share merger consideration adequately compensates AVEO’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.